The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis

Table 1 Main characteristics of all studies included in the meta-analysis

Study	Year	Country	Mean/median age	Sample size	Follow-up	Stage	Cut-off (%)	Positive (%)	Quality score	Survival analysis	Hazard ratios
Shin et al.[13]	1997	Korea	62	75	35	All	5	50.7	5	OS	Estimated
Liukkonen et al.[14]	2000	Finland	65.8	187	58.8	Superficial	10	63.6	7	PFS	Estimated
Takagi et al.[15]	2000	Japan	69.3	102	41	All	NR	77	7	OS	Estimated
Tut et al.[16]	2001	UK	68	150	33	All	8	83	5	OS	Estimated
Sgambato et al.[17]	2002	Italy	68	96	50	Superficial	25	52.1	7	OS, RFS, DFS	Estimated
Lopez-Beltran et al.[18]	2004	Spain	61	159	74.8	Superficial	15	33.3	7	OS, DFS	Estimated
Mhawech et al.[19]	2004	Switzerland	70.3	101	19	Superficial	10	53.5	6	PFS	Reported in text
Galmozzi et al.[20]	2006	Italy	NR	82	21	Muscle-invasive	10	64.6	6	OS	Reported in text
Yurakh et al.[21]	2006	Spain	NR	84	36.4	All	10	NR	7	OS, PFS	Reported in text
Shariat et al.[22]	2007	USA	63.2	74	42.3	Superficial	30	68.9	7	OS, RFS, PFS	Estimated
Lee et al.[23]	2010	Korea	67	103	31.5	All	10	29	6	OS	Reported in text
Levidou et al.[24]	2010	Greece	69	157	44.95	Muscle-invasive	40	NR	5	OS	Reported in text
Behnsawy et al.[25]	2011	Japan	NR	161	47	Superficial	20	24.8	7	RFS	Reported in text
Olsson et al.[26]	2012	Sweden	73	201	60	Superficial	10	71	7	RFS, PFS	Reported in text
Fristrup et al. A[27]	2013	Denmark	68	283	103	Superficial	20	NR	7	PFS	Reported in text
Fristrup et al. B[27]	2013	Sweden, Spain, and Taiwan	71	576	80	Superficial	20	NR	7	PFS	Reported in text

NR, not reported; OS, overall survival; RFS, recurrence-free survival; PFS, Progression-free survival; DFS, Disease-free survival; “Fristrup et al. A” here means the data in this row from Fristrup et al.[27] training cohort, “Fristrup et al. B” means the data in this row from Fristrup et al.[27] validation cohort; Study quality is listed using the results of the Newcastle-Ottawa quality assessment scale.

ISSN: 1477-7819